HLX-22
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab. HLX-22 has potent antitumor activity against advanced solid tumors[1].
Product Specifications
CAS Number
2851060-90-5
Product Name Alternative
AC101
UNSPSC
12352203
Target
EGFR
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.47
References & Citations
[1]Zhu X, et al. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial[J]. Investigational New Drugs, 2023, 41 (3) : 473-482.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
353556-01 48 Tests
6-keto-PGF1a (6-keto-prostaglandin F1a) BioAssayTM ELISA Kit (Universal) discontinued
Sign In for Pricing
View Details 353556-02 96 Tests
6-keto-PGF1a (6-keto-prostaglandin F1a) BioAssayTM ELISA Kit (Universal) discontinued
Sign In for Pricing
View Details 
361171-01 2 µg
SF20, Recombinant, Mouse (Stromal Cell-derived Growth Factor SF20, Interleukin-25, Il25, IL-25) discontinued
Sign In for Pricing
View Details 361171-02 10 µg
SF20, Recombinant, Mouse (Stromal Cell-derived Growth Factor SF20, Interleukin-25, Il25, IL-25) discontinued
Sign In for Pricing
View Details